Yin Shen

CEO at Zhongmou Therapeutics

Speaker

Dr. Yin Shen is the founder and CEO of Zhongmou Therapeutics, a clinical-stage biotechnology company developing gene and optogenetic therapies to restore vision in patients with retinal degenerative diseases. Under her leadership, the company has advanced ZM-02, a best-in-class optogenetic gene therapy currently in clinical trial (MOON study), offering a mutation-independent approach for conditions like retinitis pigmentosa.

In parallel with her industry role, Dr. Shen serves as a Distinguished Professor and Director of the Eye Institute at Wuhan University, and is an internationally recognized expert in neuro-ophthalmology and inherited retinal diseases. Dr. Shen's research focuses on the mechanisms of retinal degeneration, bipolar cell dysfunction, and therapeutic gene delivery strategies, with over 80 peer-reviewed publications in high-impact journals, including Cell Reports, Nature Communications, and Science Advances.

Dr. Shen's combined academic and entrepreneurial leadership positions her at the forefront of innovation in vision restoration.